New Bispecific Antibody Therapy is One Step Closer to Approval

Novo Nordisk has filed for FDA approval of denecimig (Mim8), an investigational subcutaneous therapy designed to treat people with hemophilia A with and without inhibitors.

Source: National Bleeding Disorders Foundation, NBDF Notes, October 2025